PWP
AQST icon

Parkwoods Wealth Partners’s Aquestive Therapeutics AQST Stock Holding History

Parkwoods Wealth Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.8K Hold
11,000
– – 0.01% 165
2026
Q1 		$45.6K Buy
+11,000
New +$44.6K 0.01% 108

Other funds holding AQST

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EAM
Everstar Asset Management Mooresville, North Carolina $207M AUM 18.14% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BFG
Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

Parkwoods Wealth Partners's AQST Position: Q2 2026 in Review

Parkwoods Wealth Partners held its Aquestive Therapeutics (AQST) position steady in Q2 2026 at 11,000 shares worth $45.8K. The position accounts for 0.01% of the portfolio, ranked #165.

Parkwoods Wealth Partners first reported a position in AQST in Q1 2026 and has held it in 2 quarters since. 57 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Parkwoods Wealth Partners held 11,000 shares of Aquestive Therapeutics worth $45.8K as of Q2 2026.
  • Parkwoods Wealth Partners left its Aquestive Therapeutics share count unchanged in Q2 2026.
  • Aquestive Therapeutics made up 0.01% of Parkwoods Wealth Partners's portfolio in Q2 2026, its #165 holding.
  • Parkwoods Wealth Partners first reported a position in Aquestive Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 57 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Parkwoods Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.